Resultados de procura - Ross, Lisa
- Mostrando 1 - 20 Resultados de 22
- Go to Next Page
-
1
-
2
-
3
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States por Ross, Lisa L., Shortino, Denise, Shaefer, Mark S.
Publicado 2018Text -
4
-
5
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57... por Small, Catherine Butkus, Margolis, David A., Shaefer, Mark S., Ross, Lisa L.
Publicado 2017Text -
6
Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data por Rodriguez, Allan E, DeJesus, Edwin, Williams, Vanessa, Irlbeck, David, Ross, Lisa, Ha, Belinda, Lancaster, Charles T
Publicado 2010Text -
7
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudi... por Robertson, Kevin, Maruff, Paul, Ross, Lisa L., Wohl, David, Small, Catherine B, Edelstein, Howard, Shaefer, Mark S.
Publicado 2018Text -
8
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens por Ross, Lisa L, Cotton, Mark F, Cassim, Haseena, Voronin, Eugeny, Givens, Naomi, Sievers, Jorg, Cheng, Katharine Y
Publicado 2015Text -
9
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects por Ross, Lisa L., Song, Ivy H., Arya, Niki, Choukour, Mike, Zong, Jian, Huang, Shu-Pang, Eley, Timothy, Wynne, Brian, Buchanan, Ann M.
Publicado 2016Text -
10
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks por Squires, Kathleen E, Young, Benjamin, Santiago, Lizette, Dretler, Robin H, Walmsley, Sharon L, Zhao, Henry H, Pakes, Gary E, Ross, Lisa L, Shaefer, Mark S
Publicado 2017Text -
11
Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine por Allen, Marchelle I., Gauthier, Josee, DesLauriers, Manon, Bourne, Eric J., Carrick, Kevin M., Baldanti, Fausto, Ross, Lisa L., Lutz, Michael W., Condreay, Lynn D.
Publicado 1999Text -
12
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT por Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Publicado 2008Text -
13
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infec... por Kumar, Princy, DeJesus, Edwin, Huhn, Gregory, Sloan, Louis, Small, Catherine Butkus, Edelstein, Howard, Felizarta, Franco, Hao, Ritche, Ross, Lisa, Stancil, Britt, Pappa, Keith, Ha, Belinda
Publicado 2013Text -
14
Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected... por Ross, Lisa L., Weinberg, Winkler G., DeJesus, Edwin, Fischl, Margaret A., Horton, Joseph H., Pappa, Keith A., Lancaster, C. Tracey, Pakes, Gary E., Smith, Kimberly Y.
Publicado 2010Text -
15
Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with... por Young, Benjamin, Squires, Kathleen E., Ross, Lisa L., Santiago, Lizette, Sloan, Louis M., Zhao, Henry H., Wine, Brian C., Pakes, Gary E., Margolis, David A., Shaefer, Mark S.
Publicado 2013Text -
16
Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial por Wohl, David A., Bhatti, Laveeza, Small, Catherine B., Edelstein, Howard, Zhao, Henry H., Margolis, David A., DeJesus, Edwin, Weinberg, Winkler G., Ross, Lisa L., Shaefer, Mark S.
Publicado 2014Text -
17
Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data por Cotton, Mark, Cassim, Haseena, Pavía-Ruz, Noris, Garges, Harmony P., Perger, Teodora, Ford, Susan L., Wire, Mary Beth, Givens, Naomi, Ross, Lisa L., Lou, Yu, Sievers, Jörg, Cheng, Katharine
Publicado 2014Text -
18
HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing por Ross, Lisa L., Horton, Joseph, Hasan, Samiul, Brown, James R., Murphy, Daniel, DeJesus, Edwin, Potter, Martin, LaMarca, Anthony, Melendez-Rivera, Ivan, Ward, Douglas, Uy, Jonathon, Shaefer, Mark S.
Publicado 2014Text -
19
The genomic road to invasion—examining the similarities and differences in the genomes of associated oral pre-cancer and cancer samples por Wood, Henry M., Daly, Catherine, Chalkley, Rebecca, Senguven, Burcu, Ross, Lisa, Egan, Philip, Chengot, Preetha, Graham, Jennifer, Sethi, Neeraj, Ong, Thian K., MacLennan, Kenneth, Rabbitts, Pamela, Conway, Caroline
Publicado 2017Text -
20
Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children por Fortuny, Claudia, Duiculescu, Dan, Cheng, Katharine, Garges, Harmony P., Cotton, Mark, Tamarirt, Desamparados Pérez, Ford, Susan L., Wire, Mary Beth, Givens, Naomi, Ross, Lisa L., Lou, Yu, Perger, Teodora, Sievers, Jörg
Publicado 2014Text